Alzheimer's disease is a genetically complex disorder; rare variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene have been shown to as much as triple an individual's risk of developing Alzheimer's disease. TREM2 is a transmembrane receptor expressed in cells of the myeloid lineage, and its association with Alzheimer's disease supports the involvement of immune and inflammatory pathways in the cause of the disease, rather than as a consequence of the disease. TREM2 variants associated with Alzheimer's disease induce partial loss of function of the TREM2 protein and alter the behaviour of microglial cells, including their response to amyloid plaques. TREM2 variants have also been shown to cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy and frontotemporal dementia. Although the low frequency of TREM2 variants makes it difficult to establish robust genotype-phenotype correlations, such studies are essential to enable a comprehensive understanding of the role of TREM2 in different neurological diseases, with the ultimate goal of developing novel therapeutic approaches.
Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes
Stroke and Amyloid-β Downregulate TREM-2 and Uch-L1 Expression that Synergistically Promote the Inflammatory Response
Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology
Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification
A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy.
Recent advances from metabolomics and lipidomics application in alzheimer's disease inspiring drug discovery.
Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders
A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer's Disease
The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases.
Increased levels of Aβ42 decrease the lifespan of ob/ob mice with dysregulation of microglia and astrocytes
The Other Side of Alzheimer's Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers
GBA , Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches
Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents
Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease
Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks.
Neuropathological Alzheimer's Disease Lesions in Nasu-Hakola Disease with TREM2 Mutation: Atypical Distribution of Neurofibrillary Changes
A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants.
Recent updates in the Alzheimer's disease etiopathology and possible treatment approaches: a narrative review of current clinical trials
Alzheimer's Disease: Genetics
Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.
Alzheimer's Disease: Microglia
Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.